Nancy Leaming and Brian Posner
The big shakeup at a badly rattled Biogen continues as 2 longtime board members hit the exits
In recent weeks we’ve seen Biogen’s CSO exit under pressure and senior marketing execs leave in an exodus as the company recoiled from a fierce backlash against the FDA’s ultra controversial approval of Aduhelm for Alzheimer’s.
Now 2 longtime board members are on the way out as well as aftershocks continue to rattle the big biotech, with all the customary handshakes and congratulatory notes you might expect.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
